Cosmo Bio Co

Cosmo Bio Co Equity

The The Equity of Cosmo Bio Co (3386.T) as of Oct 26, 2026 is 9.37 B JPY. In the previous year, The Equity was 8.97 B JPY — a change of 4.52% (higher).

Equity

9.37 BJPY

YoY

4.52%

Last updated:

In 2025, Cosmo Bio Co's equity was 9.37 B JPY, a 4.52% increase from the 8.97 B JPY equity in the previous year.

The Cosmo Bio Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
6.58 B JPY
Jan 1, 2019
6.84 B JPY
Jan 1, 2020
7.36 B JPY
Jan 1, 2021
7.79 B JPY
Jan 1, 2022
8.05 B JPY
Jan 1, 2023
8.45 B JPY
Jan 1, 2024
8.97 B JPY
Jan 1, 2025
9.37 B JPY
The Cosmo Bio Co Equity history
YEAREquityYoY
9.37 BJPY+4.52%
8.97 BJPY+6.19%
8.45 BJPY+4.88%
8.05 BJPY+3.40%
7.79 BJPY+5.83%
7.36 BJPY+7.53%
6.84 BJPY+3.98%
6.58 BJPY+3.13%
6.38 BJPY+4.01%
6.14 BJPY+3.09%
5.95 BJPY-1.64%
6.05 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Cosmo Bio Co's Equity

Cosmo Bio Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Cosmo Bio Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Cosmo Bio Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Cosmo Bio Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Cosmo Bio Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Cosmo Bio Co stock

The Equity of Cosmo Bio Co is 9.37 B JPY in 2025.

The Equity of Cosmo Bio Co changed from 8.97 B JPY to 9.37 B JPY, representing a 4.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Cosmo Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co